An innovative minimally invasive, active medical device platform for remote neurological monitoring of brain cancer patients to aid treatment/care

Opto是一家总部位于英国的医疗器械SME，其核心项目团队包括Ben Woodington博士（首席执行官）、Elise Jenkins博士（项目负责人/CTO）和Jose Lepe（产品负责人）。电气监测设备对于治疗脑癌、癫痫和帕金森病等神经系统疾病至关重要。仅在英国，这些疾病每年就影响约10.5万人。不幸的是，目前的技术在远程治疗方面进展甚微，因为它们是侵入性的，不舒服的，需要医院监测，这限制了它们的短期使用，并限制了家庭使用。这是有问题的，原因有二。首先，管理这些疾病每年花费NHS超过20亿英镑，由于持续的评估，患者的生产力损失约30亿英镑。其次，对神经系统健康的不频繁、不一致的“快照”评估并不能提供该技术的全部好处，而该技术可以帮助指导治疗，通知病情进展，并向病人提供预先警告。（约占英国居民的20%）和更低-缺乏定期旅行治疗手段的收入群体受到不成比例的影响。Opto开发了一种微创，主动医疗技术平台，使脑癌患者的远程神经监测，以帮助疾病治疗和管理。这项创新将改善患有神经系统疾病的患者的生活质量，从脑癌开始。

Opto is a UK-based medical device SME with a core project team of Dr Ben Woodington (CEO), Dr Elise Jenkins (Project Lead/CTO) and Jose Lepe (Product Lead).Electrical monitoring devices are crucial for managing neurological diseases such as brain cancer, epilepsy, and Parkinson's disease. These conditions affect around 105K people annually in the UK alone. Unfortunately, current technologies have made little headway with remote treatment, as they are invasive, uncomfortable and require hospital monitoring, which limits their use to short periods and restricts at-home use. This is problematic for two reasons. First, managing these diseases costs the NHS over £2B per year, and patients lose around £3B in productivity due to ongoing assessments. Secondly, infrequent, inconsistent 'snapshot' assessments of neurological health do not provide the full benefits of the technology, which could help guide treatment, inform disease progression and provide advance warning to patients.People who do not live near major hospitals with advanced facilities (~20 % of UK residents) and lower-income groups who lack the means to travel for treatment regularly are disproportionately affected by this.Opto has developed a minimally invasive, active medical technology platform that enables remote neurological monitoring of brain cancer patients to aid disease treatment and management. This innovation will improve the quality of life of patients suffering from neurological diseases, starting with brain cancer.